Search

Your search keyword '"Moccia, Alden A."' showing total 7 results
Start Over Author "Moccia, Alden A." Journal british journal of haematology
7 results on '"Moccia, Alden A."'

3. Prognostic value of POD24 validation in follicular lymphoma patients initially treated with chemotherapy‐free regimens in a pooled analysis of three randomized trials of the Swiss Group for Clinical Cancer Research (SAKK)

Author

Moccia, Alden Alberto, primary, Schär, Sämi, additional, Hayoz, Stefanie, additional, Pirosa, Maria Cristina, additional, Taverna, Christian, additional, Novak, Urban, additional, Kimby, Eva, additional, Ghielmini, Michele, additional, and Zucca, Emanuele, additional

Published
2020
Full Text
View/download PDF

4. Late relapse in patients with diffuse large B‐cell lymphoma: impact of rituximab on their incidence and outcome

Author

Vannata, Barbara, primary, Conconi, Annarita, additional, Winkler, Jonas, additional, Cascione, Luciano, additional, Margiotta Casaluci, Gloria, additional, Nassi, Luca, additional, Moia, Riccardo, additional, Pirosa, Maria Cristina, additional, Moccia, Alden A., additional, Stathis, Anastasios, additional, Rossi, Davide, additional, Gaidano, Gianluca, additional, and Zucca, Emanuele, additional

Published
2019
Full Text
View/download PDF

5. Prognostic value of POD24 validation in follicular lymphoma patients initially treated with chemotherapy‐free regimens in a pooled analysis of three randomized trials of the Swiss Group for Clinical Cancer Research (SAKK).

Author

Moccia, Alden Alberto, Schär, Sämi, Hayoz, Stefanie, Pirosa, Maria Cristina, Taverna, Christian, Novak, Urban, Kimby, Eva, Ghielmini, Michele, and Zucca, Emanuele

Subjects
*PROGNOSIS, *CANCER research, *LYMPHOMAS, *RITUXIMAB
Abstract

Summary: The relapse of follicular lymphoma (FL) within 24 months (POD24) of chemoimmunotherapy has been associated with poor survival. We analyzed a pooled dataset of three randomized trials including FL patients with advanced disease, conducted by the Swiss Group for Clinical Cancer Research (SAKK). Overall, POD24 was observed in 27% of 318 patients, but rate variance among studies suggested that the rituximab schedule might affect POD24 rate. POD24 was associated with lower 10‐year overall survival rates than in the reference group (69% vs. 77%; hazard ratio, 3·12; 95% confidence interval, 1·73–5·65). POD24 retains its prognostic validity in patients treated without chemotherapy and may represent a useful end‐point for future studies. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

6. Extranodal NK/ T-cell lymphoma with leukaemic presentation.

Author

Gobba, Stefania, Moccia, Alden, Stussi, Georg, Mazzucchelli, Luca, Zucca, Emanuele, and Espeli, Vittoria

Subjects
*KILLER cells, *T-cell lymphoma, *TISSUE wounds, *EPSTEIN-Barr virus, *CANCER chemotherapy, *CANCER
Abstract

The article presents a case study of a 70-year-old Caucasian woman with the leukaemic form of extranodal Natural Killer (NK)/T-cell lymphoma disease. The woman presented symptoms of necrotizing skin lesions, fatigue and fever for which the treatment includes physical examination, biopsy and chemotherapy. It states that the disease represents a rare form of lymphoma associated with Epstein-Barr virus (EBV) infection in Western countries.

Published
2013
Full Text
View/download PDF

7. Incidence, risk factors and outcome of histological transformation in follicular lymphoma

Author

Annarita Conconi, Emanuele Zucca, Alden A. Moccia, Francesco Bertoni, Chiara Lobetti-Bodoni, Paola M.V. Rancoita, Anastasios Stathis, Franco Cavalli, Luca Mazzucchelli, Michele Ghielmini, Maddalena Motta, Carlotta Ponzio, Conconi, Annarita, Ponzio, Carlotta, Lobetti Bodoni, Chiara, Motta, Maddalena, Rancoita, PAOLA MARIA VITTORIA, Stathis, Anastasio, Moccia Alden, A., Mazzucchelli, Luca, Bertoni, Francesco, Ghielmini, Michele, Cavalli, Franco, and Zucca, Emanuele

Subjects
Adult, Male, medicine.medical_specialty, Pathology, Adolescent, medicine.medical_treatment, Follicular lymphoma, Antineoplastic Agents, Gastroenterology, Disease-Free Survival, Antibodies, Monoclonal, Murine-Derived, International Prognostic Index, Risk Factors, Internal medicine, medicine, Humans, Child, Lymphoma, Follicular, Survival rate, Aged, Retrospective Studies, Chemotherapy, Performance status, business.industry, Incidence, Incidence (epidemiology), Hematology, Middle Aged, medicine.disease, Lymphoma, Survival Rate, follicular lymphoma, histological transformation, prognosis, rituximab, chemotherapy, Child, Preschool, Female, Rituximab, Lymphoma, Large B-Cell, Diffuse, business, medicine.drug
Abstract

Histological transformation (HT) into diffuse large B-cell lymphoma (DLBCL) was documented in 37 of the 281 (13%; 95% CI, 9-18) follicular lymphoma (FL) patients treated at our institute from 1979 to 2007. HT occurred at a median of 2·75 years from initial FL diagnosis and HT rate was 15% at 10 years and 26% at 14 years, with a plateau from that point onward. Patients with bulky or extranodal disease, or those diagnosed before 1990 had a significantly higher risk of HT. When initial treatment strategies were taken into account, a reduced HT risk was seen in the patients initially managed with a 'watch and wait' policy, while the risk appeared significantly increased in the small subset of 18 patients initially managed with rituximab plus chemotherapy (P = 0·0005). HT was associated with a significantly shorter cause-specific survival (P = 0·0002). Predictors of survival after HT were the Follicular Lymphoma International Prognostic Index at diagnosis, as well as age and performance status at the time of HT. Our data confirm the adverse clinical outcome of FL after HT. In keeping with previous isolated reports, our findings suggest that there is a subgroup of patients in whom HT may not occur.

Published
2012
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results